We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Triple-Negative Breast Cancer
MedXY News
EnglishTag

Triple-Negative Breast Cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Advancing Early Triple Negative Breast Cancer Care: Tissue-Free Circulating Tumor DNA Assays for Molecular Residual Disease Detection
newsmolecular residual diseasetissue-free assay

Advancing Early Triple Negative Breast Cancer Care: Tissue-Free Circulating Tumor DNA Assays for Molecular Residual Disease Detection

By MedXY|Aug 17, 2026

A recent study comparing tissue-free and tumor-informed ctDNA assays in early triple negative breast cancer reveals comparable accuracy and earlier detection of molecular residual disease, supporting tissue-free approaches for routine clini

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
newsantibody-drug conjugates
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
pembrolizumab

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

By MedXY|Jan 25, 2026

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients wi

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial
Hematology-Oncologyadjuvant therapyCarboplatin

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

By MedXY|Jan 20, 2026

The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in

KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?
newsBRCA突变olaparib

KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?

By MedXY|Jan 11, 2026

The KEYLYNK-009 trial investigated pembrolizumab plus olaparib as maintenance therapy for metastatic TNBC. While it did not meet primary PFS or OS endpoints compared to chemotherapy, the combination showed a favorable trend in BRCA-mutated

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial
newsfinancial toxicityimmunotherapy

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

By MedXY|Jan 8, 2026

The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer
newsCarboplatinchemotherapy

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

By MedXY|Jan 8, 2026

The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
newsimmunotherapyTriple-Negative Breast Cancer

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

By MedXY|Jan 8, 2026

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminati

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
newsCarboplatinneoadjuvant chemotherapy

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

By MedXY|Dec 9, 2025

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits
newscapecitabineFOXC1

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits

By MedXY|Nov 30, 2025

A 10‑year follow‑up of SYSUCC‑001 shows 1 year of metronomic capecitabine after standard adjuvant therapy improved disease‑free survival in early triple‑negative breast cancer; FOXC1 expression emerged as a potential predictive biomarker in

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan
OB/GYN & Women's HealthimmunotherapySacituzumab Govitecan

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

By MedXY|Oct 24, 2025

This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.

The Dark Side of Olive Oil: High-Oil Diets Promote Lung Metastasis in Triple-Negative Breast Cancer
Clinical UpdatesmetastasisTriple-Negative Breast Cancer

The Dark Side of Olive Oil: High-Oil Diets Promote Lung Metastasis in Triple-Negative Breast Cancer

By MedXY|Oct 8, 2025

Recent research reveals that high-fat diets rich in olive oil, while not impairing immunity, significantly promote lung metastasis of triple-negative breast cancer via a novel fatty acid-driven mechanism involving FABP5 and ALDH pathways.

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer
Clinical UpdatesCarboplatinEverolimus

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer

By MedXY|Oct 6, 2025

A phase 2 study shows adding everolimus to carboplatin significantly improves progression-free survival in advanced TNBC with manageable safety profile, indicating a potential new treatment avenue.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities